DelveInsight’s, “Erosive Esophagitis - Pipeline Insight, 2022,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Erosive Esophagitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Erosive Esophagitis: Overview
Erosive Esophagitis (EE) is a major type of gastroesophageal reflux disease (GERD), characterized by erosions in the gastric mucosa caused by acidic reflux of stomach contents into the esophagus. The symptoms of EE include: difficult swallowing, painful swallowing, chest pain, swallowed food becoming stuck in the esophagus (food impaction), heartburn, and acid regurgitation. A diagnosis of EE is based upon a thorough clinical evaluation and physical examination. Tests like Barium X-ray and endoscopy are done. Laboratory tests are done to check for Infectious esophagitis. Treatment for Erosive Esophagitis is based on treating the underlying cause of disorder, use of therapies intended to lessen symptoms, and to manage complications. Medications involved over-the-counter treatments like antacids (Maalox, Mylanta etc.), H-2-receptor blockers, such as cimetidine and ranitidine, proton pump inhibitors, such as lansoprazole and omeprazole, and Potassium-competitive acid blockers are used.
"Erosive Esophagitis - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Erosive Esophagitis pipeline landscape is provided which includes the disease overview and Erosive Esophagitis treatment guidelines. The assessment part of the report embraces, in depth Erosive Esophagitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Erosive Esophagitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Erosive Esophagitis R&D. The therapies under development are focused on novel approaches to treat/improve Erosive Esophagitis.
This segment of the Erosive Esophagitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Erosive Esophagitis Emerging Drugs
Fexuprazan: Neurogastrx
Fexuprazan is a potassium‐competitive acid pump antagonist, which reversibly blocks the proton pump that secretes gastric acids located in the cannalicular membrane. It is a next-generation of proton pump inhibitors (PPI) and is under Phase III clinical development in patients with Erosive Esophagitis.
YYD601: YooYoung Pharmaceutical
YYD601 (Esomeprazole magnesium dehydrate) is a leading proton pump inhibitor. The drug is being developed by YooYoung Pharmaceutical for the treatment of peptic ulcer and gastro-oesophageal reflux disease. The therapy is currently under Phase III clinical development for the treatment of Erosive Esophagitis.
Further product details are provided in the report……..
This segment of the report provides insights about the different Erosive Esophagitis drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 3+ key companies which are developing the therapies for Erosive Esophagitis. The companies which have their Erosive Esophagitis drug candidates in the most advanced stage, i.e. Phase III include, Neurogastrx.
DelveInsight’s report covers around 3+ products under different phases of clinical development like
Erosive Esophagitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Erosive Esophagitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Erosive Esophagitis drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Erosive Esophagitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Erosive Esophagitis – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
YYD601: YooYoung Pharmaceutical
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Azeloprazole: Eisai
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug name: Company name
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Erosive Esophagitis Key Companies
Erosive Esophagitis Key Products
Erosive Esophagitis- Unmet Needs
Erosive Esophagitis- Market Drivers and Barriers
Erosive Esophagitis- Future Perspectives and Conclusion
Erosive Esophagitis Analyst Views
Appendix
List of Table
Table 1: Total Products for Erosive Esophagitis
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Erosive Esophagitis
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Eisai
• Daewoong Pharmaceutical
• YooYoung Pharmaceutical
